Literature DB >> 8890800

Exercise limitation in chronic heart failure: central role of the periphery.

A L Clark1, P A Poole-Wilson, A J Coats.   

Abstract

The symptoms of chronic heart failure (CHF) are predominantly shortness of breath and fatigue during exercise and reduced exercise capacity. Disturbances of central hemodynamic function are no longer considered to be the major determinants of exercise capacity. The two symptoms of fatigue and breathlessness are often considered in isolation. A pulmonary abnormality is usually considered to be the cause of abnormal ventilation, and increased dead space ventilation has come to be accepted as a major cause of the increased ventilation relative to carbon dioxide production seen in CHF. Rather than decreased skeletal muscle perfusion, an intrinsic muscle abnormality is considered to be responsible for fatigue. Another abnormality seen in CHF is persistent sympathetic nervous system activation, which is difficult to explain on the basis of baroreflex activation. There is increasing evidence for the importance of skeletal muscle ergoreceptors or metaboreceptors in CHF. These receptors are sensitive to work performed, and activation results in increased ventilation and sympathetic activation. The ergoreflex appears to be greatly enhanced in CHF. We put forward the "muscle hypothesis" as an explanation for many of the pathophysiologic events in CHF. Impaired skeletal muscle function results in ergoreflex activation. In turn, this causes increased ventilation, thus linking the symptoms of breathlessness and fatigue. Furthermore, ergoreflex stimulation may be responsible for persistent sympathetic activation.

Entities:  

Mesh:

Year:  1996        PMID: 8890800     DOI: 10.1016/S0735-1097(96)00323-3

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  99 in total

Review 1.  Exercise testing in the assessment of chronic congestive heart failure.

Authors:  John G Lainchbury; A Mark Richards
Journal:  Heart       Date:  2002-11       Impact factor: 5.994

2.  Case report: exercise in a patient with acute decompensated heart failure receiving positive inotropic therapy.

Authors:  Ricard Paul E H; Robert Camarda; Laura Little Foley; Michael M Givertz; Lawrence P Cahalin
Journal:  Cardiopulm Phys Ther J       Date:  2011-06

3.  Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial: Design and rationale.

Authors:  Gordon R Reeves; David J Whellan; Pamela Duncan; Christopher M O'Connor; Amy M Pastva; Joel D Eggebeen; Leigh Ann Hewston; Timothy M Morgan; Shelby D Reed; W Jack Rejeski; Robert J Mentz; Paul B Rosenberg; Dalane W Kitzman
Journal:  Am Heart J       Date:  2016-12-28       Impact factor: 4.749

4.  Excessive breathlessness in patients with diastolic heart failure.

Authors:  K K A Witte; N P Nikitin; J G F Cleland; A L Clark
Journal:  Heart       Date:  2006-04-18       Impact factor: 5.994

5.  Anaemia and heart failure.

Authors:  A J S Coats
Journal:  Heart       Date:  2004-09       Impact factor: 5.994

Review 6.  Making the case for skeletal myopathy as the major limitation of exercise capacity in heart failure.

Authors:  Holly R Middlekauff
Journal:  Circ Heart Fail       Date:  2010-07       Impact factor: 8.790

Review 7.  Respiratory and limb muscle dysfunction in pulmonary arterial hypertension: a role for exercise training?

Authors:  Marios Panagiotou; Andrew J Peacock; Martin K Johnson
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

8.  The effects of alpha and beta blockade on ventilatory responses to exercise in chronic heart failure.

Authors:  K K A Witte; S D R Thackray; N P Nikitin; J G F Cleland; A L Clark
Journal:  Heart       Date:  2003-10       Impact factor: 5.994

Review 9.  Heart failure: What causes the symptoms of heart failure?

Authors:  A J Coats
Journal:  Heart       Date:  2001-11       Impact factor: 5.994

10.  Omega-3 fatty acid supplementation enhances stroke volume and cardiac output during dynamic exercise.

Authors:  Buddy Walser; Charles L Stebbins
Journal:  Eur J Appl Physiol       Date:  2008-06-18       Impact factor: 3.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.